PMID: 6402914Mar 1, 1983Paper

Nifedipine in chronic stable angina: a double-blind placebo-controlled crossover trial

The American Journal of Cardiology
L G Sherman, C S Liang

Abstract

Thirty patients with chronic stable angina pectoris were randomized in a double-blind prospective placebo-controlled crossover trial to assess the efficacy of nifedipine (30 to 60 mg/day orally) in controlling symptoms and objective signs of myocardial ischemia using a symptom-limited treadmill exercise test. Adverse effects that occurred during both nifedipine and placebo treatment were minor and generally well tolerated. Twenty-three patients were analyzed from the crossover phase of the study. Nifedipine significantly reduced the frequency of angina by 55% and nitroglycerin consumption by 59%, and increased exercise time by 34%. These changes were significantly greater than those in the placebo group. Hemodynamic evaluation during exercise revealed a significant reduction in systolic and diastolic blood pressures in the nifedipine group at the onset of angina and at maximal exercise without significant differences in heart rate responses in the nifedipine and placebo groups. The pressure-rate product during submaximal exercise was significantly smaller in the nifedipine group than in the placebo group, but did not differ significantly in the 2 groups at the onset of angina or on maximal exercise. Furthermore, S-T segment dep...Continue Reading

References

Jan 1, 1977·Annual Review of Pharmacology and Toxicology·A Fleckenstein
Sep 1, 1978·Circulation Research·P D HenryB E Sobel
Aug 1, 1971·Annals of Internal Medicine
Dec 1, 1969·Circulation·A N GoldbargG A Bermudez

❮ Previous
Next ❯

Citations

Jan 1, 1991·The Journal of Pharmacy and Pharmacology·H AbeM Nishikibe
Jan 1, 1991·European Journal of Clinical Pharmacology·B W KarlsonG Olsson
Aug 1, 1990·Cardiovascular Drugs and Therapy·D G Waller, V F Challenor
Jan 1, 1988·International Journal of Cardiology·C E HandlerY Najm
May 1, 1990·The American Journal of Cardiology·K R RiceP H Stone
Oct 1, 1986·The American Journal of the Medical Sciences·F Urthaler
Feb 1, 1986·Clinical Cardiology·M Y FlugelmanM S Gotsman
Oct 1, 1989·International Journal of Cardiology·H DouardJ P Broustet
Jun 1, 1989·Cardiovascular Drugs and Therapy·L H Opie
Jun 1, 1989·Cardiovascular Drugs and Therapy·V F ChallenorC F George
Feb 4, 1999·Hypertension·W B StasonT C Chalmers
Mar 1, 1987·Catheterization and Cardiovascular Diagnosis·S O GottliebJ A Brinker
Jun 15, 2017·Frontiers in Pharmacology·Théophile Godfraind
Nov 1, 1989·British Journal of Clinical Pharmacology·V F ChallenorC F George

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.